INTRODUCTION
A validated and effective gene expression-based, biomarker discovery process can be an incredibly valuable and often necessary tool in drug discovery, development, and diagnostic research. However, to successfully implement a biomarker signature discovery program and mine the most value out of such a program, one needs to have access to a broad range of expertise, both biological and statistical, as well as sophisticated tools for performing the laboratory and data analysis processes that enable research and commercial applications.
Access to these skills and the tools necessary to support biomarker or signature discovery efforts may come from internally funded and constructed resources or through exterior collaborations, or in the case of the Signature Discovery™ Program developed by Althea Technologies (San Diego, CA, USA) and Expression Analysis (Durham, NC, USA), outsourced to a sole-source development provider. Whichever direction best suits your development and validation needs, several critical steps should be closely adhered to, from both biological and statistical perspectives. Our goal here is to provide an overview and some insights that identify these critical paths along your discovery activities.
THE STATE OF DRUG DEVELOPMENT
Drug development has made great strides over the past few decades due in large part to pioneering discoveries in molecular and cellular biology. These discoveries have driven new therapeutic approaches including the use of antibodies as well as gene and whole cell therapies. Even so, the much-anticipated gold rush of new therapeutics has yet to materialize. A primary reason is that researchers underestimated the complex nature of biological systems and diseases such as cancer and cardiovascular and neurological disorders. These diseases all involve a host of different factors-both genetic and environmental-that come together in multifaceted ways to initiate disease onset and to promote its progression. As a result, it is truly challenging to understand these diseases and to identify the best ways to therapeutically intervene to prevent, arrest, and cure them.
A second major issue impacting the current blockbuster drug development strategy is a general acknowledgment that the human population is intrinsically heterogeneous. Clinicians have long expressed frustration that a course of treatment that works well in one patient may well not work at all with another, even with two patients who have the exact same disease, age, weight, gender, ethnic background, and other characteristics. If you combine the variability of individual patients with the complexity and multiple mechanisms in which a disease might manifest itself, it quickly becomes clear that a one-size-fits-all therapy is not the answer for many diseases.
More recently, the infrastructure has been established to begin to better understand complex disorders in more detail at the genetic level. The completion of the human genome project was a significant tipping point. It established a foundation to apply new molecular tools to scan the activities and responses of cells and tissues at the molecular level in greater detail and to then correlate these responses with changes in cell and tissue morphology. In particular, mRNA gene expression analysis using DNA microarrays has accelerated researchers' ability to acquire information from cells and tissues at various states.
At the same time, an effort is underway to address the second piece of the puzzle by developing therapies that address the variability of each patient's genetic makeup. Therapies for cancer in particular are beginning to respond to this approach as new drug classes are tested. This new approach requires a detailed understanding of the specific genetic background of each patient and has brought on the advent of pharmacogenomics, the study of how an individual's genetic makeup affects the body's response to drugs. Information about a patient's genotype, gene expression levels, and protein levels, as evidenced by certain "biomarkers," can shed light on a patient's state as well as his/her potential to respond to a particular therapy. The discovery and application of these biomarkers will be an essential component of new drug discovery efforts.
THE VALUE OF VALIDATED SIGNATURES
Global gene expression analysis can reveal significant information about the nature and state of cells, including disease progression, pharmacological response, and biological phenomena such as growth and development. These discoveries often point to sets of genes and gene pathways that are specifically associated with the state or change in state induced by disease. It also leads to the identification of gene sets associated with disease outcome and prognosis, as well as drug-induced responses. In many cases, only a small number of genes in the total genome (e.g., 25-500 genes) respond in a statistically significant way. The set can be further reduced by removing redundant genes. The resulting smaller subset becomes a true signature for diagnosis of the biological state and a predictor of therapeutic response.
The discovery of gene expression signatures is proving to be a powerful tool for disease diagnosis and drug discovery. For example, in oncology, microarray analysis is now being broadly applied toward the diagnosis and classification of a host of different cancers, including breast (1), kidney (2), prostate (3), and childhood cancers (4) . Microarray analysis has also been used to categorize chemotherapy response and potentially direct the course of chemotherapy, for example, in acute myeloid leukemia (5) . As has been discussed, the analysis of the data from these microarray studies often points to a relatively small number of genes that can be used for diagnosis, generally ranging from 10 to near 100.
Microarray analysis is also being applied in a variety of research applications, including areas of functional genomics often coupled with the use of short interfering RNA (siRNA), developmental genetics, as well as pharmacology and toxicology. For the latter, numerous studies have been performed that analyze gene expression responses associated with dosing or treatment with different pharmacological agents (6) (7) (8) . As was the case in oncology, these microarray studies are leading to the discovery of small gene set signatures that provide essential information about specific biological responses such as genotoxicity (9) , cytotoxicity (10), and hepatotoxicity (11) .
Although the gene expression-based biomarker discovery process holds the potential to provide powerful information that can accelerate drug discovery and diagnostic research, the depth of data is extraordinary and, as a result, requires a sophisticated analytical approach. To successfully implement a signature discovery program and mine the most value out of such a program, it is critical to access experimental and bioinformatics expertise, as well as a set of sophisticated tools capable of performing the work, enabling research and commercial applications.
EXPERIMENTAL APPROACH
The signature discovery and implementation process involves multiple stages: (i) defining the research need; (ii) developing a comprehensive and clear experimental design or plan; (iii) performing global gene expression profiling using microarrays; (iv) performing a detailed analysis of the microarray data to identify key genes, patterns, and signatures responsive to the research need; (v) translating the signatures into PCR platform assays for confirmation, validation, and utilization of the signatures in a highthroughput platform; and (vi) developing the final experimental results, conclusions, and validated gene expression signatures for use as diagnostic and research tools. The final results are biochemical assays, and in some cases, signature algorithms and software that extend the application of the signature discovery program into future research and diagnostics.
The critical aspects of successful experimental design are 4-fold: use of sufficient biological replicates; ensuring that potentially confounding factors are controlled; making comparisons between equivalent sample types (e.g., tissue types); and standardizing biological and tissue sampling as well as sample handling and storage procedures.
The payoff of adhering to these accepted best practices will be high-quality data that can readily be compared between different studies, sites, and dates, and more efficient and effective use of resources and precious patient samples.
BENEFITS OF REGULATORY COMPLIANT PERFORMANCE
It is important to establish the proper testing environment in cases where a signature discovery study is focused on the identification of biomarkers to be used in clinical studies and/or diagnostics. Planning for the submission of data in support of an investigative new drug (IND) or new drug application (NDA) should begin well before the preclinical study stages. If your objectives have the potential to involve adherence to regulatory requirements, then regulatory compliant processing early in your discovery activities will lend itself to a smoother, more cost-efficient transition of data generation downstream.
The key is to create "precedent data" (generated during the discovery phase in a regulatory compliant environment). For IND or NDA, data generated in a validated [21CFR Part 58, good laboratory practice (GLP)] compliant discovery laboratory environment hold a number of advantages. For one, it will help avoid the need to reconstruct experiments that were generated in the discovery phase. Even more importantly, it will provide precedence for generating future data with the same level of sensitivity, specificity, accuracy, and reproducibility.
For clinical diagnostic applications, precedent data generated in a GLP/CLIA environment will enable a more reliable and supportive transition through the entire development cycle. This allows clinicians to begin developing investigational use only or research use only baseline data for patients now that may be used at a later time with an approved product. The end result is that one doesn't risk the loss of historical data in addition to the expense and time of data regeneration.
Regardless of the type of laboratory you operate or the environment in which you operate and generate results, regulatory compliance requires more than just changes to your laboratory environment, it entails a commitment to maintain the objectives the regulations were written to achieve.
The Food and Drug Administration (FDA) first proposed guidelines for laboratory practices supporting nonclinical studies over three years ago. Since that time, significant changes in laboratory processes have taken place; however, overall goals and objectives of testing laboratories have remained the same. These goals are to ensure that one can maintain a well-trained technical staff; in the event of failures, errors, or omissions, corrective actions are in place; results generated are accurate and verifiable; and documentation is maintained for all processing activities (preanalytical/analytical/postanalytical).
These objectives form the cornerstones of a regulated laboratory environment and support the majority of the guidelines outlined in governing policy such as 21CFR Part 58, GLP and the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
EXPERIMENTAL DESIGN
A successful gene expression-based research project requires a well-designed experiment. The discovery question posed by the scientist can usually be defined with one of the following design formats.
Baseline Versus Experiment
This design format involves microarray measurements of control negative and positive groups (e.g., untreated vs. treated, placebo vs. therapeutic, or normal vs. disease group; see Figure  1 ). The scientist looks for differences in gene expression between the groups using steps such as normalization, filtering, statistical characterization of differential gene expression, modeling of gene expression classes or dynamics, and ultimately the identification of key gene subsets and their expression behavior.
Time Course Design
Time course design tracks dynamic response in gene expression over the course of a specific period of time or at certain time intervals throughout the duration of the experiment. The approach may be used to provide more detailed information for baseline versus experiment studies or to track temporal changes such as disease progression and pharmacological response, as well as biological phenomena such as growth and development. Time course design utilizes the same analytical steps as in a baseline versus experiment format study, including statistical modeling, cluster analysis/self-organizing maps, and supervised and unsupervised classifier algorithms. 
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Outcome and Observational Design
This format extends the baseline versus experiment model to involve multiple, interrelated parameters and the need to identify gene expression patterns associated with multiple states. Studies include the collection of global gene expression data from a clinical population and the determination of specific profiles associated with diagnostic and prognostic state, responsiveness to treatment, and/ or outcome relevance. The scientist will associate a specific gene expression pattern with each disease/state category and use these patterns to predictively identify these categories in new samples.
GLOBAL PROFILING
The primary engine of the signature discovery process is global gene expression profiling. Several different platforms of gene expression chips have become available for a growing number of species and, in most cases, enable the analysis of entire genomes for a given species.
In the experimental phase, how many chips or microarrays are needed is often a key question. Because of the relative cost per sample, it is often tempting to run too few experiments by reducing the total number of samples to be analyzed or the number of experimental replicates. If the goal is to identify differentially expressed genes with confidence, then one sample in each group may only be the beginning, depending on the nominal levels of expression in each control group of the genes of interest. Useful statistical analysis information can be generated with just one sample per group and, in some cases, that will suffice, but generally additional replicates will be needed to ensure confidence in the differences in underlying expression.
In the experimental design phase, it is important to analyze the complexity of the problem that needs to be solved and the existing knowledge base. Given a good understanding of the problem, it is often the case that statistics can be applied to predict the scope of the experiment necessary to extract the gene expression signal of interest versus other artifacts and confounding factors. In some cases, the result of such analysis will generate a model where only a dozen or so microarrays will be required, while in other cases, several hundred might be required. In cases where the model cannot be completely defined, it is standard procedure to stage the microarray analysis phase and perform a preliminary statistical assessment at each stage to recalculate the necessary scope of the experiment.
Exemplary steps in the global profiling phase include: (i) isolating the RNA from frozen tissue or cellular samples as needed (including tissue blocks, fluid samples, or cell pellets); (ii) verifying the quality of the RNA using an established platform; (iii) producing, fragmenting, and verifying the cRNA target using standard cDNA synthesis and in vitro transcription (IVT) protocols; and (iv) hybridizing the cRNA targets to arrays.
Stringent quality-control procedures need to be put into place to monitor samples through the entire process, especially when generating precedent data. These quality-control procedures apply to all samples processed in support of the signature discovery program. During the microarray analysis phase of each study, the sample quality and integrity should be checked at multiple steps, including initial RNA quality, cRNA quality and yield, efficiency of fragmentation during target preparation, and instrument performance quality control.
POST-GLOBAL PROFILING DATA ANALYSIS
Following the collection of microarray data during the global profiling stage, the data should proceed through several steps of review and analysis. In cases where the model cannot be completely defined, the data should be collected in phases, with each phase followed by a round of data analysis. Upon the successful completion of all phases, the research program is ready to move directly into full data analysis and signature discovery.
Overall, the data analysis involves several components including a phase of data qualification and then a detailed phase of data mining and analysis. In the data mining and analysis phase, specific gene expression signatures are revealed. Depending on the research goals, these biomarkers may comprise a simple gene list in which the genes are linked to a particular biological state or behavior. The biomarker signatures may also be more complex and comprise the gene set, a specific range of gene expression levels or changes, and one or more mathematical algorithms that link these levels or changes to specific phenotypic or morphological states. In all cases, the determination of gene expression levels for the specific set of genes can be used to capture and even predict biological states and effects at the cellular, organ, and even whole organism level.
DATA QUALIFICATION
The first task in a detailed analysis is to ensure that the data used will be of the required quality. In addition to basic sample quality control, it is critical to review the overall quality results for all samples in the experiment. The goal is to determine if there is unusual sample behavior in a small subset of samples that can be determined when looking at several quality-control measurements simultaneously over many samples. This is usually followed up by methods that examine overall signal in the samples.
In gene expression experiments, there are instances in which the RNA is of good quality (i.e., not degraded) and the hybridization quality-control data are also very good; however, the sample shows an expression pattern very different from its cohorts in the same clinical group. This may be due to a number of reasons unrelated to the experiments. For example, the sample may suffer from tissue heterogeneity or some factor related to its capture/extraction. It could be a previously unidentified confounding factor of some significance to the experiment (e.g., subject age). Principal component analysis is a statistical method that has been used effectively in this area to quickly identify samples that have very different expression patterns from their cohorts.
Data normalization is another key component of data qualification. There are often significant chip-to-chip differences related to various aspects of hybridization, staining, and washing. The goal of probe quantile normalization is to create the same signal distribution curve for each hybridized array. Quantile normalization (a type of normalization termed a "complete data" method) has a proven track record of making arrays more comparable under a variety of conditions even when compared to more sophisticated methods of normalization. At the same time, it provides a readily understandable and interpretable result. It also helps elicit smaller differences in log expression between replicates than simpler methods of normalization such as probe set scaling.
There has been much advancement in the methods of summarizing probe-level intensities to the transcript (probe set) level. Methods that take into account probe-specific hybridization affinities and cross-hybridization potential usually have much better performance (sensitivity and specificity) than the standard platform algorithm. Examples of alternative algorithms include the robust multi-array average (RMA), model-based expression index (MBEI; dChip), and position-dependent nearest neighbor (PDNN) model.
DATA MINING
Once the microarray data have been processed and qualified, a multi-step process can begin to mine the data for expression changes and patterns that are related to the research goals of the project. Depending on the experimental design, one or more of the following analyses should be performed.
Differential Analysis
Differential analysis is a popular type of analysis. In this analysis, the gene expression levels of two or more samples are compared to identify the genes that have changed. In many cases, a simple differential analysis can dramatically reduce the number of genes to be examined as part of a signature discovery process (e.g., reducing the number of genes from 30,000 to less than 1000).
Annotation-Based Analysis
For certain types of projects, especially functional genomics and target discovery and evaluation projects, annotation-based analytical techniques can yield interesting and immediate results about the specific associations of genes and their link to a particular biological or pharmacological activity. This analysis is an effective way to group and sort the large amount of data produced by gene expression experiments using whole-genome arrays. For example, genes related to metabolism (i.e., the metabolic pathway) or signal transduction may be represented graphically in a network-type diagram. The goal is to facilitate the examination of differential gene expression in a more suitable biological context and intuitive format. The symbology available in the software can incorporate information related to the experiment including up-and down-regulation. From this analysis, scientists can confirm relationships between genes or determine new relationships.
Unexpected gene associations can also be found by mining the literature. There are a variety of tools available that allow for efficient information retrieval from PubMed, an access mechanism to the Medline database that contains millions of abstracts from biomedical articles and papers. Many of these techniques use advanced natural language processing (NLP) technology to extract relationship-oriented information from abstracts in order to enable an evidence-based analysis of differential gene expression in an experiment.
Predictive Classifiers
Another type of analysis, predictive classifiers, associates specific gene expression responses with particular phenotypic or morphological states, responses, or outcomes. For each different state, response, or outcome, a different classifier can be developed. Exemplary classifiers relevant to drug discovery include classifiers for disease diagnosis and prognosis as well as pharmacological and toxicological responses. More basic research examples include classifiers associated with cell type, tissue type, developmental state, and response to environmental factors. These gene sets and their associated gene expression levels provide a detailed image of genetic state and function as a surrogate phenotype that often outperforms other histological and morphological end points.
Depending on the complexity, strength, and scale of the data set, the nature of the classification, and the desired output of the predictor/classifier, one or more means to predict or classify the system may be employed. Methods that are commonly used include general linear models (including logistic regression), discriminate analysis, machine learning, simple and evolutionary artificial neural networks, genetic classification trees or forests, Bayesian methods, and k nearest neighbor methods. The actual method one chooses would depend on a variety of issues related to the specific nature of the study, including the nature of what is being predicted/classified, strength and scale of the data set, and the desired output of the predictor/classifier.
A commonly used technique to ensure the robustness of the predictive model is to primarily use supervised methods of analysis involving n-fold cross-validation of the data set. The biological samples are divided into different groups or subsets to provide a training set to build a predictive model and a test set to evaluate the success of the model in terms of predictability. The process involves iteration of n-fold analytical runs in which the samples associated with the training and test sets are randomly interchanged. The technique enables an initial assessment of the reliability of the prediction/classification model that will then be validated by the next phase of the program. Cross-validation should always be performed, even in cases where supervised methods are not used.
SIGNATURE TRANSLATION
The process of mining microarray data frequently leads to the identification of a relatively small set of genes that are particularly relevant to the research needs of the scientist. The methods of data mining described above typically yield gene sets ranging from just a few to the low hundreds-most frequently less than 100 and often less than 50. As a consequence, once a small gene set signature has been discovered, it is advantageous to introduce a more costefficient, higher throughput gene expression platform (e.g., PCR) for further sample analysis. The goal is to validate the microarray discoveries and to extend the use of the gene expression signatures to the analysis of many hundreds or even thousands of additional samples.
An efficient method for the analysis of small sets of genes is universal-primed reverse transcription PCR (RT-PCR), a highly multiplexed PCR technique developed by our laboratory. Unlike real-time PCR methods that provide data on one to two genes per PCR, the universal-primed, RT-PCR method yields quantitative data on 20-35 genes per reaction. The higher levels of multiplexing and accurate quantitation are achieved using fluorescent capillary electrophoresis detection, and involve the use of very small, nanogram amounts of RNA for each analysis. The technology is low cost by nature because it uses standard reagents and off-the-shelf equipment. It has also been optimized for mid-to high-throughput applications and enables the extension of gene expression signature studies to the analysis of thousands of samples in microtiter plate format.
This technology is an ideal complement to microarray analysis and is being routinely used for microarray data validation and translation of microarray-derived signatures into higher throughput assays. Exemplary studies include the confirmation of microarray data associated with acetominophen toxicity (12) and a 20,000-compound library screen targeting the down-regulation of a set of microarray-derived prostate cancer targets (13) .
DATA AND MODEL VALIDATION AND EXPANSION
Once a gene signature has been derived from the microarray data, the scientist can use these data in several ways. Depending on the goals of the study, the scientist may wish to validate the discovered expression patterns using a secondary method. Typically, a first phase of data validation confirms the expression levels seen by microarrays by using a second technology platform. This type of validation requires the reanalysis of all or a subset of the samples used in the global profiling phase of the project for the specific genes that comprise the identified signatures. In general, a concordance level of 80%-90% between microarray and PCR platforms represents a very good level of data confirmation. With good microarray data, concordance levels can be even higher, especially when comparing expression trends as seen in time course or dose response studies. Because concordance is never 100% in cases where a classifying algorithm has been developed, it is important to rerun the classifying method using the PCR data set to refine the algorithm.
As a second phase, validation may also include expanding the data set to increase the statistical strength of the signature gene set, its associated gene expression levels and, where applicable, its associated classifier algorithm. The cost efficiencies gained by translating to a multiplexed PCR platform enable the scientist to confirm the specifics of a particular signature by significantly expanding the sample set that is used for data mining. In cases where a classifier algorithm has been developed, the probability scores (e.g., true-positive/false-positive frequencies) will generally improve with an increased sample set.
An increased sample set is often important in cases where there might be small differential subpopulations (e.g., one or a few percent) that might not be captured within the population used for initial signature discovery. Examples include cases where idiosyncratic drug response might occur within a patient population or in cancer subtypes that may be particularly different in prognosis (e.g., highly aggressive or indolent).
MULTIPLEXED PCR ANALYSIS
As a matter of standard practice, the following activities should be performed for each PCR experiment: (i) isolation of any additional RNA frozen tissue or cellular samples as needed. Depending on the samples (blocks, fluid samples, or cell pellets), the extraction may be performed in single columns or in a 96-well format. (ii) Verification of the quality and yields of the RNA and development of the PCR multiplexes. (iii) PCR data acquisition and analysis.
An important aspect in multiplex design is the selection of reference genes. Preferably, when analyzing tissue-derived samples, each multiplex includes three to five reference genes. The reference genes are a combination of classically known genes such as β-actin and cyclophilin A as well as genes that have been identified during the global profiling phase as being unchanged in the study. As part of the initial data analysis, the different reference genes are compared relative to each other. Commonly, two to three of these genes do not change in expression relative to each otherincreasing the confidence that they will function as well as reference genes in the analysis.
Using the multiplexed PCR assays, data collection and analysis can be performed using standardized PCR protocols optimized for use in microtiter plate format. The universal primer-based PCR strategy means that all multiplexes perform similarly using a single set of reaction conditions. RT-PCRs are usually run in 10-20 µL using 5-20 ng of total RNA, and analyzed by capillary electrophoresis. Following electrophoresis, the data for each gene are collected, normalized to one or more reference genes, and then exported to a database. The data are then available for query in analysis.
Finally, because of variations in protocols used to obtain biological samples, it is critical to conduct quality checks including the integrity and quantitation of the isolated RNAs, incorporating external reference RNAs as needed. The performance of the multiplexed PCR analysis in triplicate for all samples provides both expression values and coefficients of variance, enabling the performance of several different statistical tests to detect sample outliers and enhance the confidence of the scientist in the data obtained.
Validated Tools
All of the efforts of a signature and biomarker discovery program are aimed at providing critical data and a set of valuable, validated tools. The data themselves are of high value, but the real goal is to provide answers and solutions that go beyond simple data. With each study, a series of success criteria should be created. The identification and validation of specific gene sets and signatures will often represent the most important measures of success.
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